Valuation : LB Pharmaceuticals Inc

Market Cap 1.54B 1.33B 1.24B 1.14B 2.14B 147B 2.15B 14.76B 5.76B 74.28B 5.78B 5.66B 246B P/E 2026 *
-8.37x
P/E 2027 * -9.67x
Enterprise Value 1.18B 1.02B 957M 874M 1.65B 113B 1.65B 11.36B 4.43B 57.16B 4.45B 4.35B 190B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.76%
Yield 2026 *
-
Yield 2027 * -
1 day-0.33%
1 week+0.23%
Current month+19.09%
1 month+36.61%
3 months+73.37%
6 months+98.79%
Current year+114.42%
1 week 46.37
Extreme 46.37
50.16
1 month 36.72
Extreme 36.72
50.16
Current year 18.43
Extreme 18.43
50.16
1 year 13.36
Extreme 13.36
50.16
3 years 13.36
Extreme 13.36
50.16
5 years 13.36
Extreme 13.36
50.16
10 years 13.36
Extreme 13.36
50.16
Manager TitleAgeSince
Chief Executive Officer 53 19/11/2024
Director of Finance/CFO 55 01/03/2016
Chief Tech/Sci/R&D Officer - 30/06/2026
Director TitleAgeSince
Director/Board Member 76 01/07/2019
Director/Board Member 53 01/08/2023
Director/Board Member 53 19/11/2024
Date Insider Type Main position Quantity % Market Cap.
30/07/26
Deep Track Capital LP
BuyCompany 286,205 0.8872%
03/06/26 Free

Director

12,500 0.0557%
03/06/26 Free

Chairman

10,000 0.0446%
Change 5-day change 1-year change 3-year change Capi.($)
-0.33%+0.23% - - 1.54B
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-8.37%-12.43%+0.14%-15.42% 25.64B
-2.35%-5.75%-12.17%+448.29% 25.89B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
Average -1.85%-1.71%+59.31%+192.41% 28.35B
Weighted average by Cap. -1.92%-1.49%+57.15%+152.82%

Financials

2026 *2027 *
Net sales - -
Net income -176M -152M -142M -130M -245M -16.84B -246M -1.69B -659M -8.5B -662M -647M -28.19B -191M -164M -154M -141M -265M -18.22B -266M -1.83B -713M -9.2B -716M -700M -30.49B
Net Debt -355M -306M -287M -262M -493M -33.93B -495M -3.4B -1.33B -17.13B -1.33B -1.3B -56.79B -506M -436M -409M -373M -704M -48.4B -706M -4.85B -1.89B -24.43B -1.9B -1.86B -81.01B
Logo LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The Company is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
Employees
49
Date Price Change Volume
28/08/26 $47.73 -0.33% 230,559
27/08/26 $47.89 -0.57% 256,078
26/08/26 $48.17 -1.30% 244,900
25/08/26 $48.80 +1.22% 217,026
24/08/26 $48.21 +1.24% 252,689
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
47.73USD
Average target price
53.38USD
Spread / Average Target
+11.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LBRX Stock